Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated plasmodium falciparum infections

Simple item page
dc.contributor.authorDing, Junjie
dc.contributor.authorRavinetto, Raffaella
dc.contributor.authorHoglund, Richard
dc.date.accessioned2025-10-29T10:12:01Z
dc.date.available2025-10-29T10:12:01Z
dc.date.issued2024
dc.description.abstractArtemisinin-based combination therapy (ACT) is the first-line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant patient populations. This study aimed to evaluate the PK properties of amodiaquine and its active metabolite, desethylamodiaquine, and piperaquine in women in their second and third trimester of pregnancy with uncomplicated P. falciparum infections. Eligible pregnant women received either artesunate-amodiaquine (200/540 mg daily, n = 771) or dihydroartemisinin-piperaquine (40/960 mg daily, n = 755) for 3 days (NCT00852423). Population PK properties were evaluated using nonlinear mixed-effects modeling, and effect of gestational age and trimester was evaluated as covariates. 1071 amodiaquine and 1087 desethylamodiaquine plasma concentrations, and 976 piperaquine plasma concentrations, were included in the population PK analysis. Amodiaquine concentrations were described accurately with a one-compartment disposition model followed by a two-compartment disposition model of desethylamodiaquine. The relative bioavailability of amodiaquine increased with gestational age (1.25% per week). The predicted exposure to desethylamodiaquine was 2.8%–32.2% higher in pregnant women than that reported in non-pregnant women, while day 7 concentrations were comparable. Piperaquine concentrations were adequately described by a three-compartment disposition model. Neither gestational age nor trimester had significant impact on the PK of piperaquine. The predicted exposure and day 7 concentrations of piperaquine were similar to that reported in non-pregnant women. In conclusion, the exposure to desethylamodiaquine and piperaquine was similar to that in non-pregnant women. Dose adjustment is not warranted for women in their second and their trimester of pregnancy.
dc.identifier.citationDing, J., Hoglund, R.M., Tagbor, H., Tinto, H., Valéa, I., Mwapasa, V., Kalilani‐Phiri, L., Van Geertruyden, J.P., Nambozi, M., Mulenga, M. and Hachizovu, S., 2024. Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections. CPT: Pharmacometrics & Systems Pharmacology.
dc.identifier.urihttps://doi.org/10.1002/psp4.13211
dc.identifier.urihttps://hdl.handle.net/10566/21231
dc.language.isoen
dc.publisherJohn Wiley & Sons
dc.subjectArtemisinin-based combination therapy
dc.subjectmalaria
dc.subjectamodiaquine
dc.subjectpiperaquine
dc.subjectpharmacokinetic
dc.titlePopulation pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated plasmodium falciparum infections
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ding_ population pharmacokinetics of amodiaquine_2024.pdf
Size:
283.78 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (School of Pharmacy)